SI3356385T1 - 18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate - Google Patents

18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate

Info

Publication number
SI3356385T1
SI3356385T1 SI201631064T SI201631064T SI3356385T1 SI 3356385 T1 SI3356385 T1 SI 3356385T1 SI 201631064 T SI201631064 T SI 201631064T SI 201631064 T SI201631064 T SI 201631064T SI 3356385 T1 SI3356385 T1 SI 3356385T1
Authority
SI
Slovenia
Prior art keywords
psma
imaging agents
specific membrane
membrane antigen
prostate
Prior art date
Application number
SI201631064T
Other languages
English (en)
Inventor
Jens Cardinale
Martin Schafer
Klaus Kopka
Matthias Eder
Ulrike Bauder-Wuest
Michael Eisenhut
Martina Benesova
Uwe Haberkorn
Frederik L. GIESEL
Original Assignee
Deutsches Krebsforschungszentrum
Ruprecht-Karls-Universitaet Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg filed Critical Deutsches Krebsforschungszentrum
Publication of SI3356385T1 publication Critical patent/SI3356385T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI201631064T 2015-09-30 2016-09-19 18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate SI3356385T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15002800 2015-09-30
EP16164090 2016-04-06
EP16182764 2016-08-04
EP16778680.5A EP3356385B1 (en) 2015-09-30 2016-09-19 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
PCT/EP2016/001573 WO2017054907A1 (en) 2015-09-30 2016-09-19 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer

Publications (1)

Publication Number Publication Date
SI3356385T1 true SI3356385T1 (sl) 2021-04-30

Family

ID=57121178

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631064T SI3356385T1 (sl) 2015-09-30 2016-09-19 18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate

Country Status (32)

Country Link
US (3) US10815200B2 (sl)
EP (2) EP3356385B1 (sl)
JP (1) JP6824971B2 (sl)
KR (1) KR102233726B1 (sl)
CN (1) CN108026144B (sl)
AU (1) AU2016333334B2 (sl)
BR (1) BR112018005899A2 (sl)
CA (1) CA2996330A1 (sl)
CL (1) CL2018000604A1 (sl)
CO (1) CO2018003726A2 (sl)
CU (1) CU24524B1 (sl)
CY (1) CY1123790T1 (sl)
DK (1) DK3356385T3 (sl)
EA (1) EA037512B1 (sl)
ES (1) ES2844586T3 (sl)
GE (1) GEP20207106B (sl)
HR (1) HRP20210183T1 (sl)
HU (1) HUE053064T2 (sl)
IL (1) IL258378B (sl)
LT (1) LT3356385T (sl)
MX (1) MX2018004050A (sl)
MY (1) MY197061A (sl)
NZ (1) NZ739770A (sl)
PE (1) PE20181350A1 (sl)
PH (1) PH12018500701A1 (sl)
PL (1) PL3356385T3 (sl)
RS (1) RS61394B1 (sl)
SA (1) SA518391121B1 (sl)
SI (1) SI3356385T1 (sl)
TN (1) TN2018000089A1 (sl)
WO (1) WO2017054907A1 (sl)
ZA (1) ZA201801024B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7231536B2 (ja) 2016-08-10 2023-03-01 キャンサー ターゲテッド テクノロジー エルエルシー キレート化されたpsma阻害剤
DE102016122273B4 (de) 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung
WO2018098390A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
CN110272468B (zh) * 2019-05-14 2020-12-08 上海益泰医药科技有限公司 一种前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
CN111253465A (zh) * 2020-03-03 2020-06-09 复旦大学附属肿瘤医院 一种psma结合剂及其用途
WO2022167681A1 (en) 2021-02-08 2022-08-11 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
WO2023008556A1 (ja) 2021-07-30 2023-02-02 国立大学法人大阪大学 放射標識された化合物およびその用途
TW202313000A (zh) * 2021-09-01 2023-04-01 大陸商天津恆瑞醫藥有限公司 前列腺特異性膜抗原的抑制劑及其醫藥用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479470B1 (en) 1999-04-28 2002-11-12 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase
EP1409017A4 (en) 2001-06-25 2006-05-24 Drug Innovation & Design Inc CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS
AU2003205077A1 (en) 2002-01-10 2003-07-30 Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
PL2942065T3 (pl) 2006-11-08 2018-11-30 Molecular Insight Pharmaceuticals, Inc. Heterodimery kwasu glutamowego
CN103372221B (zh) 2007-01-11 2016-08-24 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
CN104774175B (zh) 2007-06-26 2019-04-16 约翰·霍普金斯大学 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
PL2187965T3 (pl) * 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
ES2376175T3 (es) 2007-09-28 2012-03-09 Bind Biosciences, Inc. Direccionamiento a células de c�?ncer usando nanopart�?culas.
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
BRPI0906797A2 (pt) 2008-01-09 2015-07-14 Molecular Insight Pharm Inc Inibidores de anidrase carbônica ix
PL2318366T3 (pl) 2008-08-01 2017-10-31 Univ Johns Hopkins Środki wiążące PSMA i ich zastosowania
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
EP2373622A2 (en) 2008-12-05 2011-10-12 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
CA3035532C (en) 2009-03-19 2021-10-26 The Johns Hopkins University Psma-targeting compounds and uses thereof
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
EP2338892A1 (en) * 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
GB201020314D0 (en) 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
CA2819850C (en) 2010-12-06 2019-07-23 John W. Babich Psma-targeted dendrimers
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EP2739316B1 (en) 2011-08-05 2019-04-10 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
MY172519A (en) 2012-12-28 2019-11-28 Tarveda Therapeutics Inc Solid polymeric controlled release nanoparticle
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
WO2015004029A1 (en) 2013-07-08 2015-01-15 Technische Universität München 18f-labeling of aromatic and heteroaromatic molecules with unprotected carboxylic acid groups
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EP3495355A1 (en) * 2013-10-18 2019-06-12 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN108514646B (zh) 2013-11-14 2021-07-16 恩多塞特公司 用于正电子发射断层术的化合物
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
EP3140282B1 (en) 2014-05-06 2019-07-10 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
EP3183236B1 (en) 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
US9956305B2 (en) 2014-09-08 2018-05-01 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
EP3011976A1 (en) 2014-10-20 2016-04-27 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
WO2016062370A1 (en) * 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016065145A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University Psma targeted reversed carbamates and methods of use thereof

Also Published As

Publication number Publication date
US20180194729A1 (en) 2018-07-12
AU2016333334A1 (en) 2018-03-08
JP6824971B2 (ja) 2021-02-03
US20210053922A1 (en) 2021-02-25
KR102233726B1 (ko) 2021-03-31
US10815200B2 (en) 2020-10-27
ZA201801024B (en) 2019-06-26
TN2018000089A1 (en) 2019-07-08
PL3356385T3 (pl) 2021-06-28
JP2018531243A (ja) 2018-10-25
CY1123790T1 (el) 2022-05-27
HUE053064T2 (hu) 2021-06-28
EP3805250A1 (en) 2021-04-14
IL258378B (en) 2021-03-25
DK3356385T3 (da) 2021-02-15
CA2996330A1 (en) 2017-04-06
PE20181350A1 (es) 2018-08-22
PH12018500701A1 (en) 2018-10-15
LT3356385T (lt) 2021-02-25
BR112018005899A2 (pt) 2018-10-16
CN108026144B (zh) 2022-02-01
MX2018004050A (es) 2018-08-01
CN108026144A (zh) 2018-05-11
EP3356385A1 (en) 2018-08-08
RS61394B1 (sr) 2021-02-26
ES2844586T3 (es) 2021-07-22
CU24524B1 (es) 2021-06-08
EA037512B1 (ru) 2021-04-06
US20230295092A1 (en) 2023-09-21
EP3356385B1 (en) 2020-11-11
HRP20210183T1 (hr) 2021-04-30
CL2018000604A1 (es) 2019-03-29
EA201890282A1 (ru) 2018-09-28
SA518391121B1 (ar) 2021-05-30
NZ739770A (en) 2019-07-26
MY197061A (en) 2023-05-23
CU20180030A7 (es) 2018-08-06
AU2016333334B2 (en) 2019-07-25
GEP20207106B (en) 2020-05-11
KR20180058822A (ko) 2018-06-01
IL258378A (en) 2018-05-31
WO2017054907A1 (en) 2017-04-06
CO2018003726A2 (es) 2018-07-19

Similar Documents

Publication Publication Date Title
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
HK1255215A1 (zh) 用於成像和治療的尿素基前列腺特異性膜抗原(psma)抑制劑
IL258378A (en) Prostate-specific membrane antigen inhibitors are labeled with 18f and used as imaging agents for prostate cancer.
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
IL251477A0 (en) Anti-ang2 antibodies and methods of use
EP3201360A4 (en) Methods for assessing risk of developing breast cancer
HK1244445A1 (zh) 使用抗-ang2抗體的方法
SG10201913528PA (en) Methods of diagnosing cancer
HK1243434A1 (zh) Igf-1r抗體及其診斷癌症的用途
HK1248730A1 (zh) Igf-1r抗體及其用於癌症診斷的用途
PT3356385T (pt) Inibidores etiquetados com 18f de antigénio de membrana específico de próstata (psma) e utilização dos mesmos como agentes de imagiologia para o cancro da próstata